APERIO hybrid thrombectomy device receives CE mark approval

3253

AperioAcandis GmbH announces that it has received European CE mark approval for its APERIO hybrid thrombectomy device. APERIO is intended for restoration of the arterial flow in patients diagnosed with ischaemic stroke due to large intracranial vascular occlusion.

APERIO hybrid thrombectomy device, the new generation of the Acandis stent retriever, is characterised by its visibility, vessel wall apposition and expansion into the clot – for efficient clot retention and fast flow restoration. “Our engineers combined the proven, reliable and effective hybrid cell design with a new visibility concept for more safety and control. The radiopaque DFT wires allow excellent full-length visibility of the device for precise alignment and permanent control during the procedure,” said Andreas Schuessler, CEO of Acandis.

With the extended product range Acandis offers the optimal device choice depending on anatomy and treatment strategy. The APERIO hybrid thrombectomy device is suitable for vessel diameters from 1.5mm up to 5.5mm and can be delivered through common 0.021’’ microcatheters.

With the development of this stent retriever, Acandis adds to its portfolio for the treatment of ischaemic stroke: thrombectomy devices (APERIO), microcatheters (NeuroSlider) and intermediate catheters (NeuroBridge)


LEAVE A REPLY

Please enter your comment!
Please enter your name here